Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Recruiting · NCT06065371 · Registry updated 2025-12-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | Biliary Tract Neoplasms, Cancer of Gastrointestinal Tract, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, biliary tract disorder, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, esophageal disorder, gastric neoplasm, intestinal disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, rectal disorder, stomach disorder | Recruiting | Phase 1 | 2025-12-19 | NCT06065371 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Gilead Sciences | 180 |
| Henry Ford Health System | 77 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Henry Ford Cancer-Detroit | Detroit | United States | 1 |